Assessment of Borrelia miyamotoi in febrile patients and ticks in Alsace, an endemic area for Lyme borreliosis in France.
Animals
Arachnid Vectors
/ microbiology
Borrelia
/ isolation & purification
DNA, Bacterial
Disease Reservoirs
/ microbiology
Fever
/ microbiology
France
/ epidemiology
Humans
Ixodes
/ microbiology
Lyme Disease
/ epidemiology
Male
Nymph
/ microbiology
Polymerase Chain Reaction
Serologic Tests
Tick Bites
/ microbiology
Tick-Borne Diseases
/ epidemiology
Borrelia miyamotoi
Borrelia miyamotoi disease
GlpQ
Post-tick bite fever
Tick-borne diseases
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
17 Apr 2020
17 Apr 2020
Historique:
received:
19
11
2019
accepted:
09
04
2020
entrez:
19
4
2020
pubmed:
19
4
2020
medline:
6
6
2020
Statut:
epublish
Résumé
Borrelia miyamotoi is a relapsing fever Borrelia species transmitted by ticks of the Ixodes ricinus complex. Human disease caused by B. miyamotoi was first described in Russia and later in the USA and Japan. Additionally, five cases of meningoencephalitis in immunocompromised patients and one case in an apparently immunocompetent patient were described. We investigated the presence of B. miyamotoi in I. ricinus nymphs and in patients suspected of human granulocytic anaplasmosis, in Alsace (France), an endemic area for I. ricinus ticks and Lyme borreliosis, using direct (PCR) and indirect diagnosis (glycerophosphoryldiester-phosphodiesterase (GlpQ) serology). Borrelia miyamotoi was found in 2.2% of 4354 ticks collected between 2013 and 2016. None of the 575 blood samples, collected from the patients suspected of HGA, was found positive for B. miyamotoi by PCR. Acute and late sera from 138 of these 575 patients were available. These paired sera were tested for IgM and IgG antibodies against the B. miyamotoi GlpQ antigen. A total of 14 out of 138 patients had at least one positive parameter (i.e. anti-GlpQ IgG and/or IgM). One patient seroconverted for IgG, and three had isolated IgM in the acute serum. These three patients were treated with doxycycline which could have prevented seroconversion. After reviewing clinical data and other biological tests performed, co-exposure among different microorganisms vectored by ticks or serological cross-reactivity could not be ruled out in these different cases. One patient had persistent IgG, which strongly suggests previous exposure to B. miyamotoi. Humans can be exposed to B. miyamotoi through tick bites in Alsace. We present serological data for possible B. miyamotoi exposure or infection of patients with fever after tick bite. Future studies should determine the incidence, clinical course and burden of this emerging tick-borne disease in other parts of Western Europe.
Sections du résumé
BACKGROUND
BACKGROUND
Borrelia miyamotoi is a relapsing fever Borrelia species transmitted by ticks of the Ixodes ricinus complex. Human disease caused by B. miyamotoi was first described in Russia and later in the USA and Japan. Additionally, five cases of meningoencephalitis in immunocompromised patients and one case in an apparently immunocompetent patient were described.
METHODS
METHODS
We investigated the presence of B. miyamotoi in I. ricinus nymphs and in patients suspected of human granulocytic anaplasmosis, in Alsace (France), an endemic area for I. ricinus ticks and Lyme borreliosis, using direct (PCR) and indirect diagnosis (glycerophosphoryldiester-phosphodiesterase (GlpQ) serology).
RESULTS
RESULTS
Borrelia miyamotoi was found in 2.2% of 4354 ticks collected between 2013 and 2016. None of the 575 blood samples, collected from the patients suspected of HGA, was found positive for B. miyamotoi by PCR. Acute and late sera from 138 of these 575 patients were available. These paired sera were tested for IgM and IgG antibodies against the B. miyamotoi GlpQ antigen. A total of 14 out of 138 patients had at least one positive parameter (i.e. anti-GlpQ IgG and/or IgM). One patient seroconverted for IgG, and three had isolated IgM in the acute serum. These three patients were treated with doxycycline which could have prevented seroconversion. After reviewing clinical data and other biological tests performed, co-exposure among different microorganisms vectored by ticks or serological cross-reactivity could not be ruled out in these different cases. One patient had persistent IgG, which strongly suggests previous exposure to B. miyamotoi.
CONCLUSIONS
CONCLUSIONS
Humans can be exposed to B. miyamotoi through tick bites in Alsace. We present serological data for possible B. miyamotoi exposure or infection of patients with fever after tick bite. Future studies should determine the incidence, clinical course and burden of this emerging tick-borne disease in other parts of Western Europe.
Identifiants
pubmed: 32303256
doi: 10.1186/s13071-020-04071-9
pii: 10.1186/s13071-020-04071-9
pmc: PMC7165395
doi:
Substances chimiques
DNA, Bacterial
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199Subventions
Organisme : ZonMW
ID : 50-52200-98-313
Organisme : ZonMW
ID : 50-52200-98-313
Organisme : Programme Hospitalier de Recherche Clinique
ID : 3960
Références
PLoS Negl Trop Dis. 2016 Mar 17;10(3):e0004539
pubmed: 26986203
Ticks Tick Borne Dis. 2018 May;9(4):938-944
pubmed: 29606622
Clin Microbiol Infect. 2018 Dec;24(12):1338.e1-1338.e7
pubmed: 29550499
Ticks Tick Borne Dis. 2012 Dec;3(5-6):406-10
pubmed: 23182274
N Engl J Med. 2013 Jan 17;368(3):240-5
pubmed: 23323900
BMC Bioinformatics. 2015 Aug 12;16:251
pubmed: 26264559
Lancet. 2013 Aug 17;382(9892):658
pubmed: 23953389
Clin Infect Dis. 2018 Jun 1;66(12):1864-1871
pubmed: 29272385
J Immunol. 2016 May 15;196(10):4185-95
pubmed: 27076681
Euro Surveill. 2019 Mar;24(11):
pubmed: 30892181
Clin Microbiol Infect. 2015 Jul;21(7):631-9
pubmed: 25700888
Emerg Infect Dis. 2018 May;24(5):860-867
pubmed: 29664394
Emerg Infect Dis. 2014 Oct;20(10):1678-82
pubmed: 25280366
Emerg Infect Dis. 2018 Sep;24(9):1770-1772
pubmed: 30124426
Emerg Infect Dis. 2019 Oct;25(10):1965-1968
pubmed: 31538916
Emerg Infect Dis. 2016 Aug;22(8):1471-3
pubmed: 27434048
Trends Parasitol. 2015 Jun;31(6):260-9
pubmed: 25892254
Clin Infect Dis. 2006 Nov 1;43(9):1089-134
pubmed: 17029130
Emerg Infect Dis. 2011 Oct;17(10):1816-23
pubmed: 22000350
Ticks Tick Borne Dis. 2016 Oct;7(6):1109-1115
pubmed: 27622976
Emerg Infect Dis. 2016 Sep;22(9):1617-20
pubmed: 27533748
Ann Intern Med. 2015 Jul 21;163(2):91-8
pubmed: 26053877
PLoS Negl Trop Dis. 2016 Oct 5;10(10):e0005042
pubmed: 27706159
Emerg Infect Dis. 2019 May;25(5):996-998
pubmed: 31002073
Parasit Vectors. 2019 Sep 6;12(1):434
pubmed: 31492171
Parasit Vectors. 2014 May 20;7:233
pubmed: 24886071
Parasit Vectors. 2017 Nov 9;10(1):558
pubmed: 29121976
New Microbes New Infect. 2014 Sep;2(5):144-9
pubmed: 25356364
Euro Surveill. 2014 Aug 28;19(34):
pubmed: 25188613
Appl Environ Microbiol. 2006 Apr;72(4):3074-8
pubmed: 16598024
Emerg Infect Dis. 2014 Aug;20(8):1391-3
pubmed: 25061761
Ann Intern Med. 2013 Jul 2;159(1):21-7
pubmed: 23817701